NASDAQ$MRUS
Merus Nv · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Merus reported a decrease in collaboration revenue for the full year 2024 compared to 2023, primarily due to decreases in Lilly and Incyte revenue, partially offset by increases in Gilead and other revenue. The company also saw a significant increase in research and development expenses and general and administrative expenses for the full year.
Merus reported a net loss of $215.326 million for the full year 2024, an increase from the $154.939 million net loss in 2023. Total revenue for the full year was $36.133 million, down from $43.947 million in 2023. The company's cash and cash equivalents stood at $293.294 million as of December 31, 2024, with total assets at $782.693 million.
- Full year 2024 collaboration revenue decreased by $7.8 million compared to 2023, primarily due to decreases in Lilly and Incyte revenue, partially offset by increases in Gilead and other revenue.
- Research and development expense for the full year 2024 increased by $84.7 million compared to 2023, driven by increased external clinical services, drug manufacturing costs, and personnel-related expenses.
- General and administrative expense for the full year 2024 increased by $23.0 million compared to 2023, mainly due to higher personnel-related expenses, consultancy expenses, and legal expenses.
- Merus' existing cash, cash equivalents, and marketable securities are expected to fund operations into 2028.
Headline financials
Revenue & EPS history
Merus · Revenue · Quarterly
$36.1M
Forward guidance
Merus expects its existing cash, cash equivalents, and marketable securities to fund operations into 2028. The company anticipates substantial enrollment in Phase 3 registrational trials for petosemtamab in 1L PD-L1+ r/m HNSCC and 2/3L r/m HNSCC by year-end 2025, with clinical data updates for petosemtamab in 1L PD-L1+ r/m HNSCC in 1H25 and initial clinical data for mCRC in 2H25.
Tailwinds
- Phase 3 registrational trials for petosemtamab in 1L PD-L1+ r/m HNSCC and 2/3L r/m HNSCC are enrolling and expected to be substantially enrolled by YE25.
- Clinical data update for petosemtamab in 1L PD-L1+ r/m HNSCC phase 2 trial is planned for 1H25.
- Initial clinical data for petosemtamab in mCRC is planned for 2H25.
- Existing cash, cash equivalents, and marketable securities are expected to fund operations into 2028.
- Randomized registration trial in HNSCC with an overall response rate endpoint could potentially support accelerated approval.
Headwinds
- Potential delays in regulatory approval could impact the ability to commercialize product candidates and generate revenue.
- The lengthy and expensive process of clinical drug development has an uncertain outcome.
- The unpredictable nature of early-stage development efforts for marketable drugs.
- Potential delays in patient enrollment for clinical trials.
- Reliance on third parties to conduct clinical trials and manufacture products may lead to unsatisfactory performance or delays.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q4 2024
+0.5%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+19.7%
Q3 2023
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -0.2% | +0.2% | +1.0% | |
| Q2 2025 | -2.8% | -4.2% | +0.1% | |
| Q1 2025 | -0.3% | +0.4% | +28.4% | |
| Q4 2024 | +1.5% | +3.6% | -18.8% | |
| Q3 2024 | -1.9% | +0.8% | -12.4% | |
| Q2 2024 | -1.8% | -5.8% | -4.3% | |
| Q1 2024 | -7.4% | -5.8% | +8.7% | |
| Q4 2023 | -0.9% | +2.3% | -8.1% | |
| Q3 2023 | +19.7% | — | — | |
| Q2 2023 | -11.7% | — | — | |
| Q1 2023 | +9.9% | — | — | |
| Q4 2022 | +4.0% | — | — | |
| Q3 2022 | -16.2% | — | — | |
| Q2 2022 | -8.4% | — | — | |
| Q1 2022 | +0.8% | — | — | |
| Q4 2021 | +6.4% | — | — | |
| Q3 2021 | +8.1% | — | — | |
| Q2 2021 | +3.0% | — | — | |
| Q1 2021 | -3.8% | — | — | |
| Q4 2020 | +3.2% | — | — | |
| Q3 2020 | -3.2% | — | — | |
| Q2 2020 | -1.5% | — | — | |
| Q1 2020 | +3.5% | — | — | |
| Q4 2019 | +11.9% | — | — | |
| Q3 2019 | -0.8% | — | — | |
| Q2 2019 | +7.7% | — | — | |
| Q1 2019 | +3.0% | — | — | |
| Q4 2018 | +3.8% | — | — | |
| Q3 2018 | +2.5% | — | — | |
| Q2 2018 | -2.8% | — | — | |
| Q1 2018 | -1.1% | — | — | |
| Q4 2017 | +2.6% | — | — | |
| Q3 2017 | -7.1% | — | — | |
| Q2 2017 | +5.0% | — | — | |
| Q1 2017 | +0.1% | — | — | |
| Q4 2016 | -3.5% | — | — | |
| Q3 2016 | +4.2% | — | — | |
| Q2 2016 | -1.5% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro